Finished product reference
Diphtheria Toxoid / Tetanus Toxoids Adsorbed Vaccine (Td) (Adult)
Injection · Parenteral · 10 dose · 5 mL
- List code
- 17874
- Pharmacologic class
- Combined toxoid vaccine (Td, adult and adolescent, reduced diphtheria content)
What it is and how it works
Contains tetanus toxoid with a reduced quantity of diphtheria toxoid, adsorbed on an aluminium adjuvant. The low diphtheria content reduces reactogenicity in older children and adults while stimulating protective antitoxin antibodies.
Indications
Primary immunisation and boosters against tetanus and diphtheria in adults and children aged 7 years and over; tetanus-prone wound management; immunisation of pregnant women to prevent maternal and neonatal tetanus.
Dosage and administration (summary)
0.5 mL by intramuscular injection; primary course of three doses in unimmunised individuals, with boosters at intervals according to the national schedule and for wound management.
Contraindications
Anaphylaxis after a previous dose or to any component; neurological complications after a previous dose of diphtheria or tetanus toxoid.
Warnings and precautions
Postpone in acute severe febrile illness, except for wound management. Too-frequent boosters increase the risk of local reactions (Arthus-type); anaphylaxis treatment must be available. Severe tetanus-prone wounds may also require tetanus immunoglobulin.
Pregnancy
Recommended in pregnancy where indicated to prevent maternal and neonatal tetanus.
Storage and supply
Store refrigerated at 2–8 °C; do not freeze.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.